Company intelligence / Profile preview

ElmediX

Ownership: Private
Employees: ~20
Development stage: Phase 1

Overview

First-in-Human study showed significant decreases in CA 19-9 after thermal treatment in pancreatic cancer patients (up to 60% decrease after a single treatment), predicting significant life extension. No severe, dose-limiting side effects were observed, only fatigue in the days following therapy[3].

Therapeutic areas: Oncology
Modalities: Thermal therapyHyperthermic treatment
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

TempoCure

Phase 1

Indications: Pancreatic cancer, Metastatic cancer

Partnerships

University Hospital Antwerp (UZA)

Beyond the preview

Go deeper on ElmediX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ElmediX.

Explore the full profile